Financial Results Announcement, Stock Movement, Presentations, and Acquisition - Analyst Notes on Universal Health Services, Tenet, Cynosure, Albany Molecular Research, and Enanta

Editor Note: For more information about this release, please scroll to bottom.

News provided by

Apr 10, 2014, 10:49 ET

NEW YORK, April 10, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Universal Health Services, Inc. (NYSE: UHS), Tenet Healthcare Corp. (NYSE: THC), Cynosure, Inc. (NASDAQ: CYNO), Albany Molecular Research Inc. (NASDAQ: AMRI), and Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Universal Health Services, Inc. Analyst Notes

On April 7, 2014, Universal Health Services, Inc. (Universal Health Services) announced that it will report its Q1 2014 financial results on April 24, 2014, after the market close. A conference call will follow on the next day, April 25, 2014, at 9:00 a.m. ET. According to Universal Health Services, a live broadcast of the conference call, as well as its replay, will be made available on its website. The full analyst notes on Universal Health Services, Inc. will be available to download free of charge at:

http://www.AnalystsReview.com/04102014/UHS/report.pdf

Tenet Healthcare Corp. Analyst Notes

On April 7, 2014, Tenet Healthcare Corp.'s (Tenet) stock decreased 4.13%, ending the day $40.15. Over the previous three trading sessions, shares of the Company have decreased 5.75%, compared with S&P 500 which has decreased 2.43% during the same trading period. The full analyst notes on Tenet Healthcare Corp. are available to download free of charge at:

http://www.AnalystsReview.com/04102014/THC/report.pdf

Cynosure, Inc. Analyst Notes

On April 2, 2014, Cynosure, Inc. (Cynosure) announced that its 21 oral abstracts and 14 e-posters are scheduled for presentation at the 34^th Annual Scientific Conference of the American Society for Laser Medicine and Surgery (ASLMS). According to the Company, the 35 presentations will discuss clinical results with the Company's products in several key areas, including skin rejuvenation and minimally invasive treatments for laser body contouring and lower face and neck revitalization, and 10 presentations will focus on new potential aesthetic indications for the Company's flagship PicoSure, Picosecond Laser Workstation, the first FDA-cleared picosecond device for tattoo removal and benign pigmented lesions. Commenting on the news, Michael Davin, Cynosure's President and CEO, said, "The research addresses the experience with Cynosure's suite of aesthetic technology, including Precision Tx, our new minimally invasive precision laser for contouring of smaller areas as well as Cellulaze and Smartlipo for cellulite and fat removal. In addition, research will be presented on multiple studies focused on our non-invasive technology for skin rejuvenation, hyperhidrosis and hair removal." The full analyst notes on Cynosure, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04102014/CYNO/report.pdf

Albany Molecular Research Inc. Analyst Notes

On April 4, 2014, Albany Molecular Research Inc. (AMRI) announced that it has completed its previously announced acquisition of Cedarburg Pharmaceuticals, Inc. for the price of $41 million, including assumption of certain liabilities. According to the Company, the transaction is consistent with its strategy to be the preeminent supplier of custom and complex drug development services and product to both the branded and generic pharmaceutical industry. The acquisition is expected to add between $13 million and $14 million to AMRI's revenue in 2014. The full analyst notes on Albany Molecular Research Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04102014/AMRI/report.pdf

Enanta Pharmaceuticals, Inc. Analyst Notes

On March 24, 2014, Enanta Pharmaceuticals, Inc. (Enanta) announced that its eight studies regarding regimens containing ABT-450, Company's lead protease inhibitor for hepatitis C virus (HCV) will be presented during the International Liver Congress (ILC) in London from April 9-12, 2014. According to the Company, studies to be presented have been categorized into four different presentations. Oral presentations include the Sapphire-II: Phase 3 Placebo-Controlled Study of Interferon-Free, Results from the Phase 2 PEARL-I Study, Sapphire-I, Results of the Phase 2 Study of M12-999. Poster presentations include P783 - Serum MIR-122 May Serve as a Biomarker for Response to Direct Acting Antivirals, P1230 - Lack of Impact of Baseline Resistance. For the late breaker oral presentation, Turquoise-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults with Compensated Cirrhosis will be presented, and finally, the P#1299 - PEARL-III: 12 Weeks of ABT-450/r/267 + ABT-333 Achieved SVR in >99% of 410 Treatment-Naïve HCV Genotype 1b-Infected Adults With or Without Ribavirin will round up the discussion. The presentations will report results of regimens containing ABT-450 identified in its ongoing collaboration with AbbVie. The full analyst notes on Enanta Pharmaceuticals, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04102014/ENTA/report.pdf

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES:

This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review